SCHEMBL9872008

SCHEMBL9872008

CCc1c(C)[nH]c(=S)[nH]c1=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.61
ALDH1A1 P00352 9/20 0.49
LMNA P02545 2/20 0.49
NPC1 O15118 1/20 0.46
NPSR1 Q6W5P4 2/20 0.44
TDP1 Q9NUW8 3/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
POLB P06746 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.40
MAPT P10636 2/20 0.40
PDE3B Q13370 1/20 0.40
PDE3A Q14432 1/20 0.40
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39
FFAR3 O14843 1/20 0.39
HCAR2 Q8TDS4 1/20 0.39
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4978570 0.83 KDM4E (0.68) KDM4EALDH1A1LMNANPC1NPSR1
SCHEMBL6632608 0.80 KDM4E (0.69) KDM4EALDH1A1LMNANPC1NPSR1
SCHEMBL14423060 0.77 TYMP (0.47) KDM4EALDH1A1LMNANPC1KMT2A
SCHEMBL1227933 0.76 KDM4E (0.59) KDM4EALDH1A1LMNANPC1NPSR1
SCHEMBL10870444 0.75 KDM4E (0.53) KDM4EALDH1A1LMNANPC1NPSR1
SCHEMBL1888814 0.72 ALDH1A1 (0.60) KDM4EALDH1A1LMNANPC1NPSR1
SCHEMBL17504394 0.72 KDM4E (0.50) KDM4EALDH1A1LMNANPC1NPSR1
SCHEMBL17376302 0.72 KDM4E (0.54) KDM4EALDH1A1LMNANPC1NPSR1
SCHEMBL11449106 0.71 ALDH1A1 (0.65) KDM4EALDH1A1LMNANPC1NPSR1
SCHEMBL9016387 0.71 KDM4E (0.38) KDM4EALDH1A1LMNANPC1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240139190-A1 NOVEL ANTIPARASITIC COMPOUNDS AND METHODS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2024-05-02 US disclosed
WO-2021077102-A1 NOVEL ANTIPARASITIC COMPOUNDS AND METHODS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-04-22 WO disclosed
US-5037830-A Antisecretory-antiulcer agents RICHTER GEDEON VEGYESZETI GYAR RT (HU) 1991-08-06 US disclosed
CN-1046158-A New sulfur uracil derivative contains pharmaceutical composition of these derivatives and preparation method thereof RICHTER GEDEON VEGYESZET (HU) 1990-10-17 CN disclosed
EP-0391254-A2 Novel thiouracil derivatives pharmaceutical compositions containing them and process for preparing same RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 1990-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240139190-A1 NOVEL ANTIPARASITIC COMPOUNDS AND METHODS TUBB, TUBB1, TUBA1C KDM4E 3028/4885ALDH1A1 3602/4885LMNA 1503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.